By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



4222 Emperor Boulevard
Suite 200
Durham  North Carolina  27703  U.S.A.
Phone: 919-485-8080 Fax: n/a


Novan, Inc. is a late-stage specialty biotechnology company focused on redefining the standard of care in dermatology through the development and commercialization of innovative therapies using the Company’s nitric oxide platform. Our ability to harness nitric oxide and its multiple mechanisms of action has enabled us to create a platform with the potential to generate differentiated, first-in-class product candidates. We are rapidly advancing programs in five dermatological conditions with significant unmet medical need. We believe that our ability to conveniently deploy nitric oxide on demand in topical formulations allows us the potential to significantly improve patient outcomes in a variety of skin diseases and positions us to be a commercially successful leader in the dermatology market.




CEO: Nathan Stasko

Chief Commercial Officer: Brian Johnson

CFO: Richard Peterson

Chief Medical Officer: M. Joyce Rico


Please click here for clinical trial information.

Key Statistics

Ownership: Private

Web Site: Novan


Company News
Novan Appoints Paula Brown Stafford, Chief Development Officer, To Board Of Directors 8/16/2017 6:57:47 AM
Novan Announces Corporate Update Conference Call And Webcast 7/26/2017 11:06:31 AM
Novan To Present Safety And Efficacy Data For SB204 Program In Adolescents At 13th World Congress Of Pediatric Dermatology 7/7/2017 9:14:29 AM
Novan Lays Off 20% of Workforce, Switches Up C-Suite 6/6/2017 5:54:43 AM
Novan Announces Leadership Adjustments And Business Update 6/5/2017 1:09:00 PM
Novan Reports First Quarter 2017 Financial Results 5/12/2017 8:22:20 AM
Novan Presents Preclinical Data From Inflammatory Skin Diseases Program 4/27/2017 8:50:43 AM
Novan Presents Safety Data For SB204 Program 4/27/2017 8:41:36 AM
Novan Reports Positive Topline Results With SB208 In Phase II Trial 4/12/2017 10:27:32 AM
Novan Reports Topline Results From SB204 Phase 3 Pivotal Trials 1/27/2017 7:43:59 AM